New diabetes clinical trial: A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus

Published on: January 15, 2026 at 11:00PM
Conditions: T2DM
Interventions: Drug: Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059））
Sponsors: The First Affiliated Hospital of Henan University of Science and Technology; PegBio Co., Ltd.
Not yet recruiting
https://ift.tt/1Rj2tPu